{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:57:33Z","timestamp":1773658653073,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.ajog.2005.03.036","type":"journal-article","created":{"date-parts":[[2005,6,20]],"date-time":"2005-06-20T16:04:21Z","timestamp":1119283461000},"page":"1849-1854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: A subanalysis of data from the OPERA trial"],"prefix":"10.1016","volume":"192","author":[{"given":"Franklin M.","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger R.","family":"Dmochowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Lama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney U.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter K.","family":"Sand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2005.03.036_bib1","series-title":"Goodman & Gilman's: the pharmacological basis of therapeutics","first-page":"141","article-title":"Muscarinic receptor agonists and antagonists","author":"Brown","year":"1996"},{"key":"10.1016\/j.ajog.2005.03.036_bib2","first-page":"13","article-title":"The mechanism of action of tolterodine","volume":"11","author":"Nilvebrant","year":"2000","journal-title":"Rev Contemp Pharmacother"},{"key":"10.1016\/j.ajog.2005.03.036_bib3","first-page":"478","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder","volume":"16","author":"Van Kerrebroeck","year":"1997","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ajog.2005.03.036_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.ajog.2005.03.036_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1067\/mob.2001.116371","article-title":"Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis","volume":"185","author":"Harvey","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2005.03.036_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1442-2042.2002.00460.x","article-title":"Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder","volume":"9","author":"Lee","year":"2002","journal-title":"Int J Urol"},{"key":"10.1016\/j.ajog.2005.03.036_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1464-410X.2002.02905.x","article-title":"A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder","volume":"90","author":"Leung","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.ajog.2005.03.036_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s001929970003","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder","volume":"10","author":"Drutz","year":"1999","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ajog.2005.03.036_bib9","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","article-title":"Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial","volume":"165","author":"Malone-Lee","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.ajog.2005.03.036_bib10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.ajog.2005.03.036_bib11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0149-2918(00)88316-2","article-title":"An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.ajog.2005.03.036_bib12","first-page":"718","article-title":"Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group","volume":"95","author":"Versi","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2005.03.036_bib13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0149-2918(01)80024-2","article-title":"A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate","volume":"23","author":"Chancellor","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.ajog.2005.03.036_bib14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2165\/00002018-200225120-00004","article-title":"A benefit-risk assessment of extended-release oxybutynin","volume":"25","author":"Michel","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.ajog.2005.03.036_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ajog.2005.03.036_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-5347(05)64115-8","article-title":"Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence","volume":"169","author":"Reinberg","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ajog.2005.03.036_bib17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ajog.2005.03.036_bib18","series-title":"COSTART: coding symbols for thesaurus of adverse reaction terms","author":"US Food and Drug Administration","year":"1995"},{"key":"10.1016\/j.ajog.2005.03.036_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00044011-200323060-00003","article-title":"Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers","volume":"23","author":"Diefenbach","year":"2003","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.ajog.2005.03.036_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00191165","article-title":"Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers","volume":"47","author":"Pietzko","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2005.03.036_bib21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/00912700122010528","article-title":"Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system","volume":"41","author":"Todorova","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2005.03.036_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","article-title":"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride","volume":"46","author":"Katz","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ajog.2005.03.036_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/009127009903900313","article-title":"Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin","volume":"39","author":"Gupta","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2005.03.036_bib24","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archinte.1997.00440350031003","article-title":"Explicit criteria for determining potentially inappropriate medication use by the elderly: an update","volume":"157","author":"Beers","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajog.2005.03.036_bib25","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1001\/archinte.163.22.2716","article-title":"Updating the Beers criteria for potentially inappropriate medication use in older adults","volume":"163","author":"Fick","year":"2003","journal-title":"Arch Intern Med"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937805004436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937805004436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:58:25Z","timestamp":1757584705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937805004436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0002937805004436"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2005.03.036","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: A subanalysis of data from the OPERA trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2005.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}